Kodiak Sciences

KOD

Market cap $1.53B

Acquired 386,000 shares of Kodiak Sciences (NASDAQ: KOD); estimated transaction value of $7.90 million based on quarterly average pricing Quarter-end Kodiak Sciences position value rose by $19.49 million, reflecting both trading and price movement Transaction represented a 1.73% increase relative to fund 13F AUM Boxer Capital Management, LLC held 1,136,000 Kodiak Sciences shares valued at $31.76 million after the trade Kodiak Sciences position now represents 6.95% of 13F AUM, which places it outside the fund's top five holdings

Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.

Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position.

Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

“Big mo” is an “eternal feature” of financial markets worldwide.

Kodiak Sciences Inc. (KOD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th Annual J.P.

IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.

PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share.